Current Report Filing (8-k)
April 20 2017 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): April 20, 2017
VBI
VACCINES INC
.
(Exact
name of registrant as specified in its charter)
British
Columbia, Canada
|
|
000-37769
|
|
N/A
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
222
Third Street, Suite 2241
|
|
|
Cambridge,
Massachusetts
|
|
02142
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
|
(Former
Name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.08 Shareholder Director Nominations.
On
April 20, 2017, the Board of Directors of VBI Vaccines Inc. (the “
Company
”) scheduled its 2017 Annual General
and Special Meeting of Shareholders (the “
2017 Annual Meeting
”) for June 22, 2017, which date is more than
30 days from the anniversary date of the Company’s 2016 Annual General and Special Meeting of Shareholders.
The
Company has set a deadline of April 26, 2017, for the receipt of shareholder proposals submitted pursuant to Rule 14a-8 under
the Securities Exchange Act of 1934, as amended (the “
Exchange Act
”), for inclusion in the Company’s
proxy materials for the 2017 Annual Meeting, which date the Company has determined to be a reasonable time before it expects to
begin to mail its proxy materials. In order to be considered timely, any such proposal must be received by the Company at its
principal executive offices at 222 Third Street, Suite 2241, Cambridge, MA 02142, Attn: Secretary, no later than 5:00 p.m. Eastern
Standard Time on April 26, 2017. Any such proposal must also meet the requirements set forth in the Company’s Articles (the
“
Articles
”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “
SEC
”)
in order to be eligible for inclusion in the proxy materials for the 2017 Annual Meeting.
A
copy of the Articles was attached as Exhibit 3.1 to our registration statement on Form F-4 (File No. 333-208761), filed with the
SEC on December 23, 2015.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VBI
Vaccines Inc.
|
|
|
|
Date:
April 20, 2017
|
By:
|
/s/
Jeff Baxter
|
|
|
Jeff
Baxter
|
|
|
President
and Chief Executive Officer
|
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2023 to Apr 2024